Serum Derivatives–Reactive Oxygen Metabolite Levels as a Marker of Clinical Conditions in Patients with Bronchial Asthma, COPD, or Asthma–COPD Overlap: A Prospective Study
Serum-Derivate-reaktive Sauerstoffmetabolit-Spiegel als Marker klinischer Zustände bei Patient:innen mit Bronchialasthma, COPD oder Asthma-COPD-Overlap: prospektive Studie
Journal of Clinical Medicine · 09.10.2024 · 13 (19) · 6022
DOI: 10.3390/jcm13196022 ↗Auf einen Blick
Bei 214 Patient:innen mit BA, COPD oder ACO waren Serum-d-ROMs bei COPD und ACO höher als bei BA. Die Werte korrelierten mit Entzündung, Symptombelastung und Atemflusslimitation.
Fragestellung
Ob Serum-d-ROMs mit klinischen Merkmalen bei BA, COPD und ACO zusammenhängen.
Methode
Prospektive Studie mit 214 Patient:innen von Juni 2020 bis Mai 2023; Erfassung von Lungenfunktion, Bluttests, Fragebögen und Serum-d-ROMs.
Ergebnisse
214 Patient:innen: 109 mit BA, 63 mit COPD, 42 mit ACO. d-ROMs waren bei COPD und ACO höher als bei BA; keine Differenz zwischen COPD und ACO. Mehrere Korrelationen mit Entzündung, Scores und Lungenfunktion.
Schlussfolgerung der Autor:innen
Serum-d-ROMs könnten ein Marker für systemische Entzündung, Symptombelastung und Luftflusslimitierung bei BA, COPD und ACO sein.
Kernaussagen
- d-ROMs waren bei COPD und ACO höher als bei BA.
- Korrelationen mit Entzündungsmarkern, Scores und Lungenfunktion.
- Kein Unterschied zwischen COPD und ACO bei d-ROMs.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.10.2024. Verfasst von Keitaro Nakamoto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kyorin University Faculty of Medicine, 6-20-2, Shinkawa, Mitaka-shi 181-8611, Tokyo, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants-In-Aid for Scientific Research (KAKENHI).
Themen: COPD
Abstract (Originalsprache)
Background
Oxidative stress plays an important role in the pathophysiology of bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), and asthma–COPD overlap (ACO), but its relevance has not been fully elucidated. The aim of this study was to measure the levels of oxidative stress and investigate its clinical significance in patients with BA, COPD, or ACO.
Methods
We recruited 214 patients between June 2020 and May 2023 (109 patients with BA, 63 with COPD, and 42 with ACO). To assess clinical conditions, we evaluated patient characteristics, results of respiratory function tests and blood tests, and administered several questionnaires. We evaluated oxidative stress using the test for derivatives–reactive oxygen metabolites (d–ROMs) in serum.
Results
The d–ROMs levels were significantly higher in patients with COPD or ACO than in patients with BA. There was no difference in serum d–ROMs levels between the COPD and ACO groups. In BA, d–ROMs levels were positively correlated with interleukin (IL)-6, IL-8, serum amyloid A (SAA), and C-reactive protein (CRP) levels; white blood cell (WBC) and neutrophil counts; and St. George’s Respiratory Questionnaire (SGRQ) scores, and they were negatively correlated with forced expiratory volume in 1 s (%FEV1) and asthma control test (ACT) score. In COPD, d–ROMs levels were positively correlated with IL-6, SAA, and CRP levels; WBC, neutrophil, and eosinophil counts; and COPD assessment test (CAT) and SGRQ scores, and they were negatively correlated with forced vital capacity (%FVC), %FEV1, and %FEV1/FVC scores. In ACO, d–ROMs levels were positively correlated with IL-6, SAA, tumor necrosis factor alpha (TNF-α), and CRP levels; and CAT and SGRQ scores, and they were negatively correlated with %FVC and %FEV1 scores.
Conclusions
Serum d–ROMs levels may serve as a marker reflecting clinical conditions such as systemic inflammation, symptom severity, and airflow limitation in patients with BA, COPD, and ACO.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Kyorin University Faculty of Medicine, 6-20-2, Shinkawa, Mitaka-shi 181-8611, Tokyo, Japan.
- Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, 3-1-24, Matsuyama, Kiyose-shi 204-8522, Tokyo, Japan.
ORCID-Profile: Keitaro Nakamoto, Jumpei Aso, Takeshi Saraya
Förderung
- Grants-In-Aid for Scientific Research (KAKENHI)
Zitieren
APA
Nakamoto, K., Watanabe, M., Saito, M., Kasuga, K., Miyaoka, C., Yoshida, Y., Kobayashi, F., Nunokawa, H., Aso, J., Nakamoto, Y., Ishida, M., Sada, M., Honda, K., Takata, S., Saraya, T., Shimoda, M., Tanaka, Y., Saotome, M., Ohta, K., & Ishii, H. (2024). Serum Derivatives–Reactive Oxygen Metabolite Levels as a Marker of Clinical Conditions in Patients with Bronchial Asthma, COPD, or Asthma–COPD Overlap: A Prospective Study. Journal of Clinical Medicine, 13(19), 6022. https://doi.org/10.3390/jcm13196022
Vancouver
Nakamoto K, Watanabe M, Saito M, Kasuga K, Miyaoka C, Yoshida Y, et al. Serum Derivatives–Reactive Oxygen Metabolite Levels as a Marker of Clinical Conditions in Patients with Bronchial Asthma, COPD, or Asthma–COPD Overlap: A Prospective Study. Journal of Clinical Medicine. 2024;13(19):6022. doi:10.3390/jcm13196022
BibTeX
@article{Nakamoto2024,
author = {Nakamoto, Keitaro and Watanabe, Masato and Saito, Masaoki and Kasuga, Keisuke and Miyaoka, Chika and Yoshida, Yuki and Kobayashi, Fumi and Nunokawa, Hiroki and Aso, Jumpei and Nakamoto, Yasuo and Ishida, Manabu and Sada, Mitsuru and Honda, Kojiro and Takata, Saori and Saraya, Takeshi and Shimoda, Masafumi and Tanaka, Yoshiaki and Saotome, Mikio and Ohta, Ken and Ishii, Haruyuki},
title = {Serum Derivatives–Reactive Oxygen Metabolite Levels as a Marker of Clinical Conditions in Patients with Bronchial Asthma, COPD, or Asthma–COPD Overlap: A Prospective Study},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {19},
pages = {6022},
doi = {10.3390/jcm13196022}
}
EUVIMED